Streptococcus Pneumoniae Serotype 24F Conjugate Vaccine
This is a pneumococcal conjugate vaccine that targets Streptococcus pneumoniae serotype 24F, a strain responsible for invasive pneumococcal disease and pneumonia. The vaccine works by linking the capsular polysaccharide antigen to the diphtheria CRM197 protein carrier to enhance immune response, particularly in populations like infants and young children who typically respond poorly to polysaccharide antigens alone.
A conjugate vaccine providing targeted protection against pneumococcal disease caused by serotype 24F through immune system stimulation via polysaccharide-protein conjugation.
Key facts at a glance
- RxNorm
- 2686923
- Generic
- Streptococcus Pneumoniae Serotype 24f Capsular Antigen Diphtheria Crm197 Protein Conjugate Vaccine
- Class
- unclassified
- Brands
- Capvaxive
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Prevention of invasive pneumococcal disease, pneumonia, meningitis, and other infections caused by Streptococcus pneumoniae serotype 24F. Serotype 24F has been identified as an emerging cause of pneumococcal disease globally and is included in newer expanded-valency pneumococcal conjugate vaccines.
The vaccine contains the capsular polysaccharide from S. pneumoniae serotype 24F, chemically conjugated to the nontoxic diphtheria toxin mutant CRM197 protein. This conjugation converts a T-cell independent antigen into a T-cell dependent antigen, enhancing immunogenicity by enabling better antibody production, immunological memory, and response in young children whose immune systems cannot effectively respond to polysaccharides alone.
As a conjugate vaccine, it may be used in pediatric populations where traditional polysaccharide vaccines are ineffective. Administration schedule typically follows standard childhood immunization recommendations. Common side effects include injection site reactions, fever, and irritability. Like all vaccines, it may not provide complete protection in all recipients, and serotype replacement remains a consideration for overall pneumococcal disease prevention.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 31, 2026. · Read our editorial policy